BioSpace News Archive

First Wave BioPharma, Inc. announced that its Board of Directors declared a dividend of 0.001 of a share of newly-designated Series F Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 p.m. Eastern Time on December 5, 2022.

Lifecore Biomedical, Inc. announced the closing of a $5 million private placement of its common stock with affiliates of Wynnefield Capital, Inc., a longtime stockholder of the Company, at $7.97 per share.

Oncopeptides AB announced that the company has entered into a renewed unsecured loan facility agreement with the European Investment Bank, granting access to a conditional loan facility of up to €30 million.

Kaplan Fox & Kilsheimer LLP is continuing to investigate claims on behalf of investors in Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ: SPPI) securities.

XORTX Therapeutics Inc. has received notification from the Nasdaq Stock Market LLC Listing Qualifications Department that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Rule 5550 since the closing bid price for the Company’s common shares listed on Nasdaq was below US$1.00 for 30 consecutive business days.

Isofol Medical AB, announced that analysis of the AGENT study’s final data confirmed topline results presented on August 3, 2022.

inQB8 Medical Technologies, LLC, in Partnership with Peijia Medical Limited, announced that it has successfully implanted the MonarQ Transcatheter Tricuspid Valve in a 75-year-old female suffering from severe torrential Tricuspid Regurgitation.

Venus Medtech is building an exciting pipeline of treatments for structural heart disease. The company will present its products at the conference taking place at the ExCeL London November 27-29, 2022 in its booth (#25), during a symposium, and at the official launch of the TARGET multicenter clinical study.

RadNet, Inc. today announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the BofA Securities 2022 Leveraged Finance Conference in Boca Raton, FL on Tuesday, November 29, 2022 at 11:50 a.m. Pacific Time (2:50 p.m. Eastern Time).

Spectrum Pharmaceuticals, Inc. today announced that the Company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding Spectrum’s New Drug Application (NDA) for poziotinib for the treatment of patients with previously treated locally advanced or metastatic non-small cell lung cancer (“NSCLC”) harboring HER2 exon 20 insertion mutations.